ImmPACT Bio USA procures $18m

ImmPACT Bio USA Inc, an Israeli developer of novel cell therapies for treating cancer, has raised $18 million in funding.

ImmPACT Bio USA Inc, an Israeli developer of novel cell therapies for treating cancer, has raised $18 million in funding. The investors included OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda Ventures, Inc., RM Global Partners BioPharma Investment Fund, Novartis Venture Fund, Bukwang Pharmaceutical, Hayan Health Networks Inc and JVC Investment Partners.

Source: Press Release